Molecular diagnostics laboratory P23 Labs reported on Friday the availability of its new P23 Respiratory ONE test to detect respiratory illnesses that share symptoms with COVID-19 when test results for COVID-19 are negative and the patient is still not healthy.
The company added that the P23 Respiratory ONE can detect the common cold, five different Influenza strains and five Coronavirus strains including COVID-19. The test results are available 48 hours from lab receipt.
According to the company, the P23 Respiratory ONE takes a single COVID-19 sample, whether it is the non-invasive saliva sample or the nasal swab sample. The kits are shipped directly to patients to allow sample collection from the comfort of their own home.
If anyone is presenting COVID-19 symptoms and working with their physician to obtain a COVID-19 order, the patient should also tell their physician that they would like to have a test that identifies what illness they do have if it is not COVID-19, concluded the company.
IDEAYA Biosciences submits IND for IDE892; Targets Phase 1 in 4Q 2025
Airiver medical receives FDA approval for central airway stenosis trial
INOVIO to begin rolling submission of BLA for INO-3107
Calluna Pharma begins Phase 2 study of CAL101 in idiopathic pulmonary fibrosis
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Innovent Biologics receives approval over squamous cell lung cancer study
Novocure submits FDA PMA for Tumor Treating Fields therapy in pancreatic cancer
HUTCHMED completes enrollment in Phase III SANOVO trial of ORPATHYS and TAGRISSO in China
LivaNova announces commercial launch of Essenz Perfusion System in China
Precigen's PAPZIMEOS granted US FDA approval to treat with recurrent respiratory papillomatosis
Leads Biolabs completes patient enrollment in pivotal Opamtistomig trial for EP-NEC
BioDlink's bevacizumab injection secures Colombia and Pakistan marketing authorisation